A University of Toronto study is providing reassuring evidence about the consumption of soy foods by postmenopausal women.* ...

SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving surgery, adjuvant tamoxifen reduced their ...

MONDAY, Dec. 16, 2024 (HealthDay News) -- The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast cancer, ...

The estimated 15-year risk of ipsilateral recurrence was 11.4% for patients treated with tamoxifen and 19% for patients who did not receive tamoxifen, a statistically significant difference. When ...

Citation: Clinical trial: Adjuvant tamoxifen may reduce recurrence risk for patients with 'good-risk' DCIS who forgo radiation (2024, December 12) retrieved 6 January 2025 from https ...

The charity’s much-loved events, which raise funds for life-saving research, are taking place in Ayr on June 1 and anyone who ...

SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the ...

MONDAY, Dec. 16, 2024 (HealthDay News) -- The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast ...

Broadcaster and DJ Adele Roberts is urging people to kick start the New Year by signing up for Cancer Research UK’s Race for ...

At 15 years, patients who had received immediate surgery had lower rates of distant recurrence and breast cancer death.

The charity’s much-loved events, which raise funds for life-saving research, are returning to hundreds of venues across the ...

Tamoxifen reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen is metabolized to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome ...